bioRxivCancer BiologyPreprint
Patient-specific detection of cancer genes reveals recurrently perturbed processes in esophageal adenocarcinoma
Thanos P. MourikisiD, Lorena BenedettiiD, Elizabeth FoxalliD, Damjan TemelkovskiiD, Joel NulseniD, Juliane PerneriD, Matteo CeredaiD, Jesper LagergreniD, Michael Howell, Christopher YauiD, Rebecca C. Fitzgerald, Paola ScaffidiiD, Francesca D. CiccarelliiD, on behalf of the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium
Abstract
The identification of somatic alterations with a cancer promoting role is challenging in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we developed a machine learning algorithm to identify cancer genes in individual patients considering all types of damaging alterations simultaneously (mutations, copy number alterations and structural rearrangements). Analysing 261 EACs from the OCCAMS Consortium, we discovered a large number of novel cancer genes that, together with well-known drivers, help promote cancer. Validation using 107 additional EACs confirmed the robustness of the approach. Unlike known drivers whose alterations recur across patients, the large majority of the newly discovered cancer genes are rare or patient-specific. Despite this, they converge towards perturbing cancer-related processes, including intracellular signalling, cell cycle regulation, proteasome activity and Toll-like receptor signalling. Recurrence of process perturbation, rather than individual genes, divides EACs into six clusters that differ in their molecular and clinical features and suggest patient stratifications for personalised treatments. By experimentally mimicking or reverting alterations of predicted cancer genes, we validated their contribution to cancer progression and revealed EAC acquired dependencies, thus demonstrating their potential as therapeutic targets.
- organism: human
- assay: whole-exome sequencing
- research focus: variant calling
- approach: machine learning (classical)
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The landscape of selection in 551 Esophageal Adenocarcinomas defines genomic biomarkers for the clinic
A. M. Frankell, S. Jammula, … The Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium·Nature GeneticsPeer-reviewed·Feb 4, 2019
- Mapping Functional Tumor Suppressor Networks in Esophageal Adenocarcinoma Using In Vivo CRISPR Screening and Perturb-sequencing
Ebtihal H Mustafa, Katherine Papastratos, … Nicholas James Clemons·bioRxiv·Jul 21, 2026
- Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma
Josephine Yates, Camille A. Mathey-Andrews, … Eliezer M. Van Allen·Cell Reports MedicinePeer-reviewed·Jun 1, 2025
- Extrachromosomal DNA in the cancerous transformation of Barrett's esophagus
Jens Luebeck, Alvin Wei Tian Ng, … Paul S. Mischel·bioRxiv·Jul 25, 2022
- High Content Phenotypic Profiling in Oesophageal Adenocarcinoma Identifies Selectively Active Pharmacological Classes of Drugs for Repurposing and Chemical Starting Points for Novel Drug Discovery
R. E. Hughes, R. J. R. Elliott, … N. O. Carragher·bioRxiv·Jan 20, 2020
- Identification of the Novel Pyroptosis-Related Gene Signature in Patients with Esophageal Adenocarcinoma
Ruijie Zeng, Shujie Huang, … Hao Hui Chen·bioRxiv·Jul 5, 2021